We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Refining HbA1c Thresholds for Accurate Type 1 Diabetes Progression Risk in Islet Autoantibody-Positive Adults

MedXY Editorial Team•Jul 12, 2026•Diabetes & Endocrinology
autoantibodiesHbA1crisk stratificationtype 1 diabetes

Highlight

The accuracy of HbA1c thresholds to predict type 1 diabetes progression in islet autoantibody-positive adults improves when accounting for age-related increases in HbA1c. Traditional thresholds tend to overestimate risk in adults compared to children. Applying an age-adjusted HbA1c or a higher fixed threshold (≥6.0% [42 mmol/mol]) better aligns progression risk across age groups, particularly among those aged 30 and older.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical FactorsA novel, cumulative risk factor approach identifies patients at increased risk for additional retinal intervention after laser retinopexy for retinal tears, improving surveillance and management strategies.Sep 15, 2026Advancing SGLT Inhibitor Use for Heart and Kidney Protection in Type 1 Diabetes: Opportunities and ChallengesThis article reviews expert perspectives on the efficacy and safety of SGLT inhibitors for cardiovascular and renal disease in type 1 diabetes, outlines translational insights from type 2 diabetes data, and proposes a roadmap for regulatorySep 15, 2026β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody PositivityAssessment of β-cell dysfunction using stimulated glucose and C-peptide measures improves risk stratification for type 1 diabetes progression among single autoantibody-positive relatives, enabling personalized monitoring and targeted intervSep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy
A novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.
Sep 15, 2026
New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 DiabetesAn international expert consensus recommends practical principles and minimum requirements for general‑population screening for islet autoantibodies to detect early-stage type 1 diabetes, reduce DKA, enable early care and access to disease‑Sep 13, 2026
Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol AnalysisThe PROTECT trial’s per-protocol analysis confirms teplizumab’s efficacy in preserving beta cell function, reducing insulin needs, and improving glycemic control in children and adolescents newly diagnosed with stage 3 type 1 diSep 13, 2026